III.

IV.

V.

he

.

e

.

.

°

e

e

e

Control Populations

a

2.

°

. .... 2...

. 2... 1. 6 ee ee ee ee ee ee

10

HEMATOLOGIC CBSERVATIONS . . 2... 1 0 ee ee ew we ee ee we eee es
A. Backgrovwd 2. 2 1 6 0 et we we ww we tt we ww we we ww

16
16

Results

B.
C.

Methods
. . 2. 2 2. 2 2 ee
Results and Discussion . .

.

.

.

2.

6

©

©

©

ee

we

we

wwe

ee et
. 1...

GROWTH AND DEVELOPMENT ........
A. Background . .......-+e2..

ew we
1 ee

we

ee

we

wee

ee

we

we wh
ee

tt
ew ew

th
we

th
ee ew

we ee
ee ew

a
ee ee we we we ee

B.
Methods
.......-46e6-.
ee ee ew ee wt the we thw
C.
Results
. 2.1. 6 6 0 ee ew ew ee ee tw et tt th hhh
D.
Discussion ....
oe eee
.
oe ee ee we wee
AGING, IMMUNOLOGICAL, CHROMOSOME, AND. GEYE. Ic STUDIES
A.
Aging Studies
2... 6 2 6 ee we we ee ee we ee ee et

Immunological Studies .......
ee ee we ww ee we
Chromosome and Genetic Studies ...-...
rr
1. Chromosome Studies . ..... 2.2.28.
we ee et ww
2. Isoleucine Misincorporation in Heagoglobin A of Marshallese
3. Detection of Mutant Proteins ......
ee ee we

PARASITOLOGIC SURVEYS AND SUPPRESSIVE ANTI-RELMINTH TREATMENT ON
RONGELAP AND UTIRIK, 1977-1979 . 2... 2 ew 2 0 ew ww we we we we we www
B.

C.

16
18

26
26
26
28
28

32

32
33
33
35
36

8G

Results and Discussion . . 1... 2 2 2s ee ee ew ew ew we we we we

38

Methods

...

2.

6

2

ee

ee

ww

ew we

te

A.

Malignancies . . 1... 1 1 eee ee tw

C.

Pituitary Tumor

Benign Tumers

et

we

we

we

eh

whe

et ww

36

eee ee te tt
te wee we wee ewe we we eo ee)

47
AD

rr

53

. . 2. 2. 2 0 se wt ew ee eee eee ee ee ew eB

THYROID ABNORMALITIES

A.

ll

Background . 2... 6 2 ee we ew we ee te ee ee ee thet ee)

D.
Conclusions
.....+s-.
DIABETES SURVEY
...
eee
NEOPLASIA (NON-THYROID) ec eee ee ew ee

B.

IX.

Eazly Radiation

C.

A.

VII.
VIII.

......4ee-6

1.

2.
Residual Radiation . ......66-6
E.
Data Evaluation
.......s.e-s
GENERAL MEDICAL SURVEYS
.
ee ee we
A.
Background ........
B.
Methods
.....-2+246.-6e
l.
Procedures ........

B.
C.

VI.

Dosimetric Evaluation

LGD
OOYHNYNUUNUWWNR RE RH KS

II.

Early Clinical Effects ........2...
e

D.

o

C.

°

I.

eee

DEDICATION . . . . . 2. +. 2. ese
PREFACE
...
se ee ee ww
ACKNOWLEDGMENTS wee ee ees
INTRODUCTION ......22-22--.
A.
Background .........-.
B.
The Accident ......2...

. 2... 1. 1 ee ee
.

.

.

A

Background (Chronology of Developments)

- xii -

a2 e

Select target paragraph3